As a soft tissue sarcoma, liposarcoma is an uncommon malignancy that starts in fat cells. It usually appears in the abdomen, limbs, or other places with adipose tissue. Location-specific symptoms can include lumps, discomfort, or swelling. Well-differentiated, myxoid, round-cell, dedifferentiated, and pleomorphic liposarcomas are common varieties. Surgery is typically used for treatment, though it can occasionally be paired with chemotherapy or radiation. Genetic disorders and previous radiation exposure are risk factors. The liposarcoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the liposarcoma pipeline analysis include Boehringer Ingelheim, Adaptimmune, and Salarius Pharmaceuticals, LLC among others.
Leading drugs currently in the pipeline include Brigimadlin, and Seclidemstat, among others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Liposarcoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into liposarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Liposarcoma therapeutics. The liposarcoma report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The liposarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with liposarcoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liposarcoma.
There are genetic and histological differences among the subtypes of liposarcoma in its pathogenesis. The retroperitoneum is frequently the site of well-differentiated liposarcomas, which are linked to chromosomal amplifications in region 12q13-15 involving oncogenes such as MDM2 and CDK4. Dedifferentiated liposarcomas can arise from scratch and are more aggressive. Whereas pleomorphic liposarcomas entail mutations in tumor suppressors such p53, myxoid liposarcomas have gene fusions (DDIT3-FUS) that promote cell proliferation. Different growth patterns and recurrence risks are displayed by each subtype.
Surgery is the main treatment for liposarcoma, with the goal of removing the tumor with clear margins to avoid recurrence. Radiation therapy can be used to reduce the tumor before surgery or to get rid of any remaining cancer cells following surgery. Although its efficacy varies by subtype, chemotherapy is taken into consideration in situations that are aggressive or metastatic. Targeted medicines like as immunotherapy and CDK4/6 inhibitors are examples of advanced treatments, especially for genetic profiles. Clinical trials investigate innovative strategies.
With a global prevalence of roughly 0.25 cases per 100,000 people, liposarcoma is the second most prevalent soft tissue sarcoma in adults. With age-standardized rates of 6.2 cases per million people, liposarcomas make up 10% of soft tissue sarcomas in England. The incidence is twice as high in males as in females, and it peaks between the ages of 75 and 85. Across all ethnic groups, middle-aged and elderly persons are the most affected.
This section of the report covers the analysis of liposarcoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total liposarcoma clinical trials.
In the liposarcoma pipeline, maximum candidates are concentrated in Phase II with 56% of the projects followed by Phase I with 25% of candidates. The rest 19% of candidates are in Phase III. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the liposarcoma pipeline analysis include monoclonal antibodies, peptides, small molecules and gene therapy. The liposarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Liposarcoma.
The EMR report for the liposarcoma pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in liposarcoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for liposarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of liposarcoma drug candidates.
Boehringer Ingelheim developed the experimental oral MDM2-p53 antagonist brigimadlin (BI 907828). By restoring p53 activity, it targets cancers with MDM2 amplification and wild-type TP53, resulting in apoptosis and cell cycle arrest. The drug is presently in Phase 3 clinical trials for several tumors, such as glioblastoma, biliary tract cancer, and dedifferentiated liposarcoma. Its potential anticancer activity and tolerable safety profile have been shown in preliminary studies.
Seclidemstat, developed by Salarius Pharmaceuticals, is an oral LSD1 inhibitor under investigation in a Phase 1/2 trial for treating relapsed or refractory Ewing sarcoma and related sarcomas, including myxoid liposarcoma. The study comprises three arms; one combining seclidemstat with chemotherapy for Ewing sarcoma, and two evaluating it as a single agent in myxoid liposarcoma and FET-rearranged sarcomas. Interim results indicate disease control in some patients. Salarius is collaborating with the FDA to analyze the data and determine the appropriate path forward.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Ewing Sarcoma Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
